Overview of Glp 1 Prescribing Among Teens With Obesity

Among the 270,170 adolescent patients with obesity , the average rate of AOM semaglutide prescriptions for adolescents with obesity within 100 days of an encounter was 0.9%. This was an increase of 88.2% or 1.9-fold higher than the rate in 2023, which was 0.5%.

New treatment options are changing the way physicians approach adolescent obesity , but experts emphasize that medication is only one part of a comprehensive health plan.
Prescribing of GLP

This retrospective cohort study examined national prescribing patterns of glucagon like peptide 1 receptor agonists (GLP1RAs) for U.S. adolescents with obesity using electronic health record data from over 2 million patients aged 12 to 17 years between 2021 and 2025. Among eligible adolescents, only 0.9 received a GLP1RA prescription, though use increased after semaglutide approval in December ...
Key Takeaways GLP-1 receptor agonist prescribing for adolescents with obesity is increasing but remains uncommon, with fewer than 1 % of eligible youths receiving a prescription despite strong evidence for meaningful weight loss. Significant disparities persist at the prescribing stage, particularly among adolescents insured by Medicaid and those from racially, socioeconomically, and ...
Useful Notes on Glp 1 Prescribing Among Teens With Obesity
This study examines the prescribing of glucagon-like peptide-1 receptor agonists for adolescents with obesity and associated disparities.
Obesity remains highly prevalent among children in the United States and is associated with an ever-increasing burden of obesity -related diseases. Effective pediatric obesity prevention and treatment will require both societal interventions and health care system innovation. One recent advancement is the approval of glucagon-like peptide-1 receptor agonists ( GLP -1RAs) for use in adolescents ...

Prescriptions for Obesity Medications Among ...
Prescribing prevalence was higher among girls, White adolescents, those aged 15-17 years, and adolescents with severe obesity . What are the implications for public health practice?
Adolescents and young adults in the U.S. are increasingly using popular GLP-1 weight-loss drugs alone or in conjunction with metabolic and bariatric surgery (MBS) to manage obesity .

Efficacy and Safety of GLP
This systematic review and meta-analysis assesses the efficacy and safety of glucagon-like peptide-1 receptor agonists ( GLP-1 RAs) in children and adolescents with obesity , prediabetes, or type 2 diabetes.






A once-weekly, 2.4-mg dose of subcutaneous semaglutide, a glucagon-like peptide-1 receptor agonist, is used to treat obesity in adults, but assessment of the drug in adolescents has been lacking. I...